These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1166 related articles for article (PubMed ID: 22882665)

  • 1. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kala-azar and post-kala-azar dermal leishmaniasis, Assam, India.
    Khan AM; Dutta P; Khan SA; Baruah SK; Raja D; Khound K; Mahanta J
    Emerg Infect Dis; 2014 Mar; 20(3):487-9. PubMed ID: 24565057
    [No Abstract]   [Full Text] [Related]  

  • 7. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
    J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
    Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
    Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.
    Dey A; Singh S
    Infect Genet Evol; 2007 Mar; 7(2):219-22. PubMed ID: 17027344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.
    Rahman KM; Islam S; Rahman MW; Kenah E; Ghalib CM; Zahid MM; Maguire J; Rahman M; Haque R; Luby SP; Bern C
    Clin Infect Dis; 2010 Jan; 50(1):73-6. PubMed ID: 19951168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
    Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
    Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
    Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
    Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge, stigma, health seeking behaviour and its determinants among patients with post kalaazar dermal leishmaniasis, Bihar, India.
    Garapati P; Pal B; Siddiqui NA; Bimal S; Das P; Murti K; Pandey K
    PLoS One; 2018; 13(9):e0203407. PubMed ID: 30192805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
    Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
    Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.